nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—liver cancer	0.244	1	CbGaD
Fluoxetine—HTR2C—Sorafenib—liver cancer	0.089	0.205	CbGbCtD
Fluoxetine—CYP2B6—Sorafenib—liver cancer	0.0553	0.127	CbGbCtD
Fluoxetine—CYP3A5—Sorafenib—liver cancer	0.0435	0.1	CbGbCtD
Fluoxetine—CYP2C19—Sorafenib—liver cancer	0.0351	0.081	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—liver cancer	0.0335	0.0773	CbGbCtD
Fluoxetine—CYP1A2—Sorafenib—liver cancer	0.0324	0.0747	CbGbCtD
Fluoxetine—CYP2C9—Sorafenib—liver cancer	0.0292	0.0673	CbGbCtD
Fluoxetine—ABCB1—Sorafenib—liver cancer	0.0283	0.0653	CbGbCtD
Fluoxetine—CYP2D6—Sorafenib—liver cancer	0.0267	0.0615	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—liver cancer	0.0172	0.0396	CbGbCtD
Fluoxetine—CYP3A4—Sorafenib—liver cancer	0.017	0.0391	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—liver cancer	0.0162	0.0373	CbGbCtD
Fluoxetine—CYP3A4—Doxorubicin—liver cancer	0.0103	0.0237	CbGbCtD
Fluoxetine—Ataxia—Epirubicin—liver cancer	0.000219	0.000972	CcSEcCtD
Fluoxetine—Dehydration—Epirubicin—liver cancer	0.000217	0.000961	CcSEcCtD
Fluoxetine—Hyponatraemia—Doxorubicin—liver cancer	0.000216	0.00096	CcSEcCtD
Fluoxetine—Osteoarthritis—Doxorubicin—liver cancer	0.000216	0.000956	CcSEcCtD
Fluoxetine—Diplopia—Doxorubicin—liver cancer	0.000216	0.000956	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000216	0.000956	CcSEcCtD
Fluoxetine—Liver function test abnormal—Epirubicin—liver cancer	0.000215	0.000954	CcSEcCtD
Fluoxetine—Dry skin—Epirubicin—liver cancer	0.000214	0.000947	CcSEcCtD
Fluoxetine—Orthostatic hypotension—Epirubicin—liver cancer	0.000213	0.000944	CcSEcCtD
Fluoxetine—Migraine—Doxorubicin—liver cancer	0.000212	0.000941	CcSEcCtD
Fluoxetine—Affect lability—Doxorubicin—liver cancer	0.000212	0.000941	CcSEcCtD
Fluoxetine—Hypokalaemia—Epirubicin—liver cancer	0.000212	0.000941	CcSEcCtD
Fluoxetine—Diarrhoea—Sorafenib—liver cancer	0.000212	0.00094	CcSEcCtD
Fluoxetine—Breast disorder—Epirubicin—liver cancer	0.000211	0.000934	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00021	0.000931	CcSEcCtD
Fluoxetine—Face oedema—Doxorubicin—liver cancer	0.000208	0.000923	CcSEcCtD
Fluoxetine—Gastritis—Epirubicin—liver cancer	0.000206	0.000915	CcSEcCtD
Fluoxetine—Muscular weakness—Epirubicin—liver cancer	0.000206	0.000911	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000206	0.000911	CcSEcCtD
Fluoxetine—Cardiac arrest—Doxorubicin—liver cancer	0.000205	0.000909	CcSEcCtD
Fluoxetine—Dizziness—Sorafenib—liver cancer	0.000205	0.000909	CcSEcCtD
Fluoxetine—Mood swings—Doxorubicin—liver cancer	0.000204	0.000906	CcSEcCtD
Fluoxetine—Abdominal distension—Epirubicin—liver cancer	0.000203	0.000899	CcSEcCtD
Fluoxetine—Ataxia—Doxorubicin—liver cancer	0.000203	0.000899	CcSEcCtD
Fluoxetine—Asthma—Epirubicin—liver cancer	0.000201	0.000893	CcSEcCtD
Fluoxetine—Influenza—Epirubicin—liver cancer	0.000201	0.000893	CcSEcCtD
Fluoxetine—Dysphagia—Epirubicin—liver cancer	0.000201	0.000893	CcSEcCtD
Fluoxetine—Dehydration—Doxorubicin—liver cancer	0.000201	0.000889	CcSEcCtD
Fluoxetine—Eosinophilia—Epirubicin—liver cancer	0.000199	0.000884	CcSEcCtD
Fluoxetine—Liver function test abnormal—Doxorubicin—liver cancer	0.000199	0.000883	CcSEcCtD
Fluoxetine—Dry skin—Doxorubicin—liver cancer	0.000198	0.000876	CcSEcCtD
Fluoxetine—Pancreatitis—Epirubicin—liver cancer	0.000197	0.000876	CcSEcCtD
Fluoxetine—Vomiting—Sorafenib—liver cancer	0.000197	0.000874	CcSEcCtD
Fluoxetine—Orthostatic hypotension—Doxorubicin—liver cancer	0.000197	0.000873	CcSEcCtD
Fluoxetine—Hypokalaemia—Doxorubicin—liver cancer	0.000196	0.00087	CcSEcCtD
Fluoxetine—Angina pectoris—Epirubicin—liver cancer	0.000196	0.00087	CcSEcCtD
Fluoxetine—Rash—Sorafenib—liver cancer	0.000195	0.000867	CcSEcCtD
Fluoxetine—Dermatitis—Sorafenib—liver cancer	0.000195	0.000866	CcSEcCtD
Fluoxetine—Breast disorder—Doxorubicin—liver cancer	0.000195	0.000864	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000194	0.000861	CcSEcCtD
Fluoxetine—Headache—Sorafenib—liver cancer	0.000194	0.000861	CcSEcCtD
Fluoxetine—Bronchitis—Epirubicin—liver cancer	0.000194	0.000859	CcSEcCtD
Fluoxetine—Pancytopenia—Epirubicin—liver cancer	0.000191	0.000848	CcSEcCtD
Fluoxetine—Gastritis—Doxorubicin—liver cancer	0.000191	0.000846	CcSEcCtD
Fluoxetine—Muscular weakness—Doxorubicin—liver cancer	0.00019	0.000843	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00019	0.000843	CcSEcCtD
Fluoxetine—Dysuria—Epirubicin—liver cancer	0.000188	0.000835	CcSEcCtD
Fluoxetine—Abdominal distension—Doxorubicin—liver cancer	0.000188	0.000832	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Epirubicin—liver cancer	0.000187	0.00083	CcSEcCtD
Fluoxetine—Asthma—Doxorubicin—liver cancer	0.000186	0.000826	CcSEcCtD
Fluoxetine—Influenza—Doxorubicin—liver cancer	0.000186	0.000826	CcSEcCtD
Fluoxetine—Dysphagia—Doxorubicin—liver cancer	0.000186	0.000826	CcSEcCtD
Fluoxetine—Pollakiuria—Epirubicin—liver cancer	0.000186	0.000825	CcSEcCtD
Fluoxetine—Eosinophilia—Doxorubicin—liver cancer	0.000185	0.000818	CcSEcCtD
Fluoxetine—Nausea—Sorafenib—liver cancer	0.000184	0.000816	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Epirubicin—liver cancer	0.000184	0.000815	CcSEcCtD
Fluoxetine—Weight increased—Epirubicin—liver cancer	0.000183	0.000813	CcSEcCtD
Fluoxetine—Pancreatitis—Doxorubicin—liver cancer	0.000183	0.00081	CcSEcCtD
Fluoxetine—Weight decreased—Epirubicin—liver cancer	0.000182	0.000808	CcSEcCtD
Fluoxetine—Hyperglycaemia—Epirubicin—liver cancer	0.000182	0.000806	CcSEcCtD
Fluoxetine—Angina pectoris—Doxorubicin—liver cancer	0.000182	0.000805	CcSEcCtD
Fluoxetine—Pneumonia—Epirubicin—liver cancer	0.000181	0.000801	CcSEcCtD
Fluoxetine—Drowsiness—Epirubicin—liver cancer	0.00018	0.000796	CcSEcCtD
Fluoxetine—Bronchitis—Doxorubicin—liver cancer	0.000179	0.000795	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000178	0.00079	CcSEcCtD
Fluoxetine—Pancytopenia—Doxorubicin—liver cancer	0.000177	0.000785	CcSEcCtD
Fluoxetine—Renal failure—Epirubicin—liver cancer	0.000177	0.000783	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Epirubicin—liver cancer	0.000176	0.000781	CcSEcCtD
Fluoxetine—Stomatitis—Epirubicin—liver cancer	0.000175	0.000776	CcSEcCtD
Fluoxetine—Jaundice—Epirubicin—liver cancer	0.000175	0.000776	CcSEcCtD
Fluoxetine—Conjunctivitis—Epirubicin—liver cancer	0.000175	0.000774	CcSEcCtD
Fluoxetine—Urinary tract infection—Epirubicin—liver cancer	0.000175	0.000774	CcSEcCtD
Fluoxetine—Dysuria—Doxorubicin—liver cancer	0.000174	0.000773	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000173	0.000768	CcSEcCtD
Fluoxetine—Sweating—Epirubicin—liver cancer	0.000172	0.000763	CcSEcCtD
Fluoxetine—Pollakiuria—Doxorubicin—liver cancer	0.000172	0.000763	CcSEcCtD
Fluoxetine—Haematuria—Epirubicin—liver cancer	0.000171	0.000759	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Doxorubicin—liver cancer	0.00017	0.000754	CcSEcCtD
Fluoxetine—Weight increased—Doxorubicin—liver cancer	0.00017	0.000752	CcSEcCtD
Fluoxetine—Epistaxis—Epirubicin—liver cancer	0.000169	0.000751	CcSEcCtD
Fluoxetine—Weight decreased—Doxorubicin—liver cancer	0.000169	0.000748	CcSEcCtD
Fluoxetine—Sinusitis—Epirubicin—liver cancer	0.000168	0.000747	CcSEcCtD
Fluoxetine—Hyperglycaemia—Doxorubicin—liver cancer	0.000168	0.000746	CcSEcCtD
Fluoxetine—Pneumonia—Doxorubicin—liver cancer	0.000167	0.000741	CcSEcCtD
Fluoxetine—Drowsiness—Doxorubicin—liver cancer	0.000166	0.000737	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000165	0.000731	CcSEcCtD
Fluoxetine—Bradycardia—Epirubicin—liver cancer	0.000164	0.000728	CcSEcCtD
Fluoxetine—Renal failure—Doxorubicin—liver cancer	0.000163	0.000724	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Doxorubicin—liver cancer	0.000163	0.000722	CcSEcCtD
Fluoxetine—Haemoglobin—Epirubicin—liver cancer	0.000162	0.000719	CcSEcCtD
Fluoxetine—Jaundice—Doxorubicin—liver cancer	0.000162	0.000718	CcSEcCtD
Fluoxetine—Stomatitis—Doxorubicin—liver cancer	0.000162	0.000718	CcSEcCtD
Fluoxetine—Rhinitis—Epirubicin—liver cancer	0.000162	0.000717	CcSEcCtD
Fluoxetine—Conjunctivitis—Doxorubicin—liver cancer	0.000162	0.000716	CcSEcCtD
Fluoxetine—Urinary tract infection—Doxorubicin—liver cancer	0.000162	0.000716	CcSEcCtD
Fluoxetine—Hepatitis—Epirubicin—liver cancer	0.000161	0.000715	CcSEcCtD
Fluoxetine—Haemorrhage—Epirubicin—liver cancer	0.000161	0.000715	CcSEcCtD
Fluoxetine—Hypoaesthesia—Epirubicin—liver cancer	0.00016	0.000711	CcSEcCtD
Fluoxetine—Pharyngitis—Epirubicin—liver cancer	0.00016	0.00071	CcSEcCtD
Fluoxetine—Sweating—Doxorubicin—liver cancer	0.000159	0.000706	CcSEcCtD
Fluoxetine—Oedema peripheral—Epirubicin—liver cancer	0.000159	0.000704	CcSEcCtD
Fluoxetine—Haematuria—Doxorubicin—liver cancer	0.000158	0.000703	CcSEcCtD
Fluoxetine—Epistaxis—Doxorubicin—liver cancer	0.000157	0.000695	CcSEcCtD
Fluoxetine—Sinusitis—Doxorubicin—liver cancer	0.000156	0.000691	CcSEcCtD
Fluoxetine—Visual impairment—Epirubicin—liver cancer	0.000155	0.000689	CcSEcCtD
Fluoxetine—Erythema multiforme—Epirubicin—liver cancer	0.000152	0.000676	CcSEcCtD
Fluoxetine—Bradycardia—Doxorubicin—liver cancer	0.000152	0.000673	CcSEcCtD
Fluoxetine—Tinnitus—Epirubicin—liver cancer	0.00015	0.000667	CcSEcCtD
Fluoxetine—Haemoglobin—Doxorubicin—liver cancer	0.00015	0.000665	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—liver cancer	0.00015	0.000663	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—liver cancer	0.000149	0.000662	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—liver cancer	0.000149	0.000662	CcSEcCtD
Fluoxetine—Hypoaesthesia—Doxorubicin—liver cancer	0.000148	0.000658	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—liver cancer	0.000148	0.000657	CcSEcCtD
Fluoxetine—Oedema peripheral—Doxorubicin—liver cancer	0.000147	0.000652	CcSEcCtD
Fluoxetine—Chills—Epirubicin—liver cancer	0.000145	0.000641	CcSEcCtD
Fluoxetine—Arrhythmia—Epirubicin—liver cancer	0.000144	0.000639	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—liver cancer	0.000144	0.000637	CcSEcCtD
Fluoxetine—Alopecia—Epirubicin—liver cancer	0.000142	0.000632	CcSEcCtD
Fluoxetine—Mental disorder—Epirubicin—liver cancer	0.000141	0.000626	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—liver cancer	0.000141	0.000625	CcSEcCtD
Fluoxetine—Malnutrition—Epirubicin—liver cancer	0.00014	0.000622	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—liver cancer	0.000139	0.000617	CcSEcCtD
Fluoxetine—Flatulence—Epirubicin—liver cancer	0.000138	0.000613	CcSEcCtD
Fluoxetine—Tension—Epirubicin—liver cancer	0.000138	0.000611	CcSEcCtD
Fluoxetine—Dysgeusia—Epirubicin—liver cancer	0.000137	0.000609	CcSEcCtD
Fluoxetine—Nervousness—Epirubicin—liver cancer	0.000136	0.000604	CcSEcCtD
Fluoxetine—Back pain—Epirubicin—liver cancer	0.000136	0.000602	CcSEcCtD
Fluoxetine—Muscle spasms—Epirubicin—liver cancer	0.000135	0.000598	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—liver cancer	0.000134	0.000594	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—liver cancer	0.000133	0.000591	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—liver cancer	0.000132	0.000585	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—liver cancer	0.000131	0.00058	CcSEcCtD
Fluoxetine—Ill-defined disorder—Epirubicin—liver cancer	0.00013	0.000577	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—liver cancer	0.00013	0.000576	CcSEcCtD
Fluoxetine—Anaemia—Epirubicin—liver cancer	0.00013	0.000575	CcSEcCtD
Fluoxetine—Agitation—Epirubicin—liver cancer	0.000129	0.000572	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—liver cancer	0.000128	0.000567	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—liver cancer	0.000127	0.000565	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—liver cancer	0.000127	0.000564	CcSEcCtD
Fluoxetine—Malaise—Epirubicin—liver cancer	0.000127	0.000561	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—liver cancer	0.000126	0.000559	CcSEcCtD
Fluoxetine—Vertigo—Epirubicin—liver cancer	0.000126	0.000559	CcSEcCtD
Fluoxetine—Syncope—Epirubicin—liver cancer	0.000126	0.000558	CcSEcCtD
Fluoxetine—Leukopenia—Epirubicin—liver cancer	0.000126	0.000557	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—liver cancer	0.000126	0.000557	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—liver cancer	0.000125	0.000554	CcSEcCtD
Fluoxetine—Palpitations—Epirubicin—liver cancer	0.000124	0.00055	CcSEcCtD
Fluoxetine—Loss of consciousness—Epirubicin—liver cancer	0.000123	0.000547	CcSEcCtD
Fluoxetine—Cough—Epirubicin—liver cancer	0.000122	0.000543	CcSEcCtD
Fluoxetine—Convulsion—Epirubicin—liver cancer	0.000122	0.000539	CcSEcCtD
Fluoxetine—Hypertension—Epirubicin—liver cancer	0.000121	0.000537	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—liver cancer	0.00012	0.000534	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—liver cancer	0.00012	0.000532	CcSEcCtD
Fluoxetine—Chest pain—Epirubicin—liver cancer	0.000119	0.00053	CcSEcCtD
Fluoxetine—Myalgia—Epirubicin—liver cancer	0.000119	0.00053	CcSEcCtD
Fluoxetine—Arthralgia—Epirubicin—liver cancer	0.000119	0.00053	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—liver cancer	0.000119	0.000529	CcSEcCtD
Fluoxetine—Anxiety—Epirubicin—liver cancer	0.000119	0.000528	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000119	0.000526	CcSEcCtD
Fluoxetine—Discomfort—Epirubicin—liver cancer	0.000118	0.000523	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—liver cancer	0.000117	0.000519	CcSEcCtD
Fluoxetine—Dry mouth—Epirubicin—liver cancer	0.000117	0.000518	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—liver cancer	0.000117	0.000517	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—liver cancer	0.000116	0.000516	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—liver cancer	0.000116	0.000515	CcSEcCtD
Fluoxetine—Confusional state—Epirubicin—liver cancer	0.000115	0.000512	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—liver cancer	0.000115	0.000509	CcSEcCtD
Fluoxetine—Anaphylactic shock—Epirubicin—liver cancer	0.000115	0.000508	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—liver cancer	0.000114	0.000506	CcSEcCtD
Fluoxetine—Infection—Epirubicin—liver cancer	0.000114	0.000505	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—liver cancer	0.000113	0.000503	CcSEcCtD
Fluoxetine—Shock—Epirubicin—liver cancer	0.000113	0.0005	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—liver cancer	0.000113	0.000499	CcSEcCtD
Fluoxetine—Thrombocytopenia—Epirubicin—liver cancer	0.000112	0.000497	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—liver cancer	0.000112	0.000497	CcSEcCtD
Fluoxetine—Tachycardia—Epirubicin—liver cancer	0.000112	0.000496	CcSEcCtD
Fluoxetine—Skin disorder—Epirubicin—liver cancer	0.000111	0.000493	CcSEcCtD
Fluoxetine—Hyperhidrosis—Epirubicin—liver cancer	0.000111	0.000491	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—liver cancer	0.000111	0.00049	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—liver cancer	0.000111	0.00049	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—liver cancer	0.000111	0.00049	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—liver cancer	0.00011	0.000489	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00011	0.000487	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—liver cancer	0.000109	0.000484	CcSEcCtD
Fluoxetine—Anorexia—Epirubicin—liver cancer	0.000109	0.000484	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—liver cancer	0.000108	0.000479	CcSEcCtD
Fluoxetine—Hypotension—Epirubicin—liver cancer	0.000107	0.000475	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—liver cancer	0.000107	0.000474	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—liver cancer	0.000106	0.00047	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—liver cancer	0.000105	0.000467	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000104	0.000463	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—liver cancer	0.000104	0.000462	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—liver cancer	0.000104	0.00046	CcSEcCtD
Fluoxetine—Insomnia—Epirubicin—liver cancer	0.000104	0.000459	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—liver cancer	0.000103	0.000459	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—liver cancer	0.000103	0.000456	CcSEcCtD
Fluoxetine—Paraesthesia—Epirubicin—liver cancer	0.000103	0.000456	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—liver cancer	0.000102	0.000454	CcSEcCtD
Fluoxetine—Dyspnoea—Epirubicin—liver cancer	0.000102	0.000453	CcSEcCtD
Fluoxetine—Somnolence—Epirubicin—liver cancer	0.000102	0.000452	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—liver cancer	0.000101	0.000448	CcSEcCtD
Fluoxetine—Dyspepsia—Epirubicin—liver cancer	0.000101	0.000447	CcSEcCtD
Fluoxetine—Decreased appetite—Epirubicin—liver cancer	9.96e-05	0.000442	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—liver cancer	9.9e-05	0.000439	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Epirubicin—liver cancer	9.89e-05	0.000439	CcSEcCtD
Fluoxetine—Fatigue—Epirubicin—liver cancer	9.87e-05	0.000438	CcSEcCtD
Fluoxetine—Pain—Epirubicin—liver cancer	9.79e-05	0.000434	CcSEcCtD
Fluoxetine—Constipation—Epirubicin—liver cancer	9.79e-05	0.000434	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—liver cancer	9.66e-05	0.000428	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—liver cancer	9.59e-05	0.000425	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—liver cancer	9.52e-05	0.000422	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—liver cancer	9.45e-05	0.000419	CcSEcCtD
Fluoxetine—Feeling abnormal—Epirubicin—liver cancer	9.44e-05	0.000419	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—liver cancer	9.42e-05	0.000418	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Epirubicin—liver cancer	9.37e-05	0.000415	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—liver cancer	9.33e-05	0.000414	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—liver cancer	9.21e-05	0.000409	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—liver cancer	9.15e-05	0.000406	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—liver cancer	9.14e-05	0.000405	CcSEcCtD
Fluoxetine—Urticaria—Epirubicin—liver cancer	9.1e-05	0.000404	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—liver cancer	9.06e-05	0.000402	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—liver cancer	9.06e-05	0.000402	CcSEcCtD
Fluoxetine—Abdominal pain—Epirubicin—liver cancer	9.05e-05	0.000402	CcSEcCtD
Fluoxetine—Body temperature increased—Epirubicin—liver cancer	9.05e-05	0.000402	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—liver cancer	8.73e-05	0.000387	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—liver cancer	8.67e-05	0.000384	CcSEcCtD
Fluoxetine—Hypersensitivity—Epirubicin—liver cancer	8.44e-05	0.000374	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—liver cancer	8.42e-05	0.000373	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—liver cancer	8.38e-05	0.000372	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—liver cancer	8.38e-05	0.000372	CcSEcCtD
Fluoxetine—Asthenia—Epirubicin—liver cancer	8.22e-05	0.000364	CcSEcCtD
Fluoxetine—Pruritus—Epirubicin—liver cancer	8.1e-05	0.000359	CcSEcCtD
Fluoxetine—Diarrhoea—Epirubicin—liver cancer	7.84e-05	0.000348	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—liver cancer	7.81e-05	0.000346	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—liver cancer	7.6e-05	0.000337	CcSEcCtD
Fluoxetine—Dizziness—Epirubicin—liver cancer	7.57e-05	0.000336	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—liver cancer	7.5e-05	0.000333	CcSEcCtD
Fluoxetine—Vomiting—Epirubicin—liver cancer	7.28e-05	0.000323	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—liver cancer	7.25e-05	0.000322	CcSEcCtD
Fluoxetine—Rash—Epirubicin—liver cancer	7.22e-05	0.00032	CcSEcCtD
Fluoxetine—Dermatitis—Epirubicin—liver cancer	7.22e-05	0.00032	CcSEcCtD
Fluoxetine—Headache—Epirubicin—liver cancer	7.18e-05	0.000318	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—liver cancer	7.01e-05	0.000311	CcSEcCtD
Fluoxetine—Nausea—Epirubicin—liver cancer	6.8e-05	0.000302	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—liver cancer	6.74e-05	0.000299	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—liver cancer	6.68e-05	0.000296	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—liver cancer	6.68e-05	0.000296	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—liver cancer	6.64e-05	0.000294	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—liver cancer	6.29e-05	0.000279	CcSEcCtD
Fluoxetine—CYP3A5—Metabolism—GSTM1—liver cancer	1.03e-05	0.000107	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GOT2—liver cancer	1.03e-05	0.000107	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP2E1—liver cancer	1.03e-05	0.000106	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CSF2—liver cancer	1.02e-05	0.000106	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—RAF1—liver cancer	1.02e-05	0.000106	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GOT2—liver cancer	1.02e-05	0.000106	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.02e-05	0.000106	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTA2—liver cancer	1.02e-05	0.000106	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—H2AFX—liver cancer	1.01e-05	0.000105	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL2—liver cancer	1.01e-05	0.000104	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HPGDS—liver cancer	1.01e-05	0.000104	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP1A1—liver cancer	1e-05	0.000104	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1e-05	0.000104	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CB—liver cancer	9.96e-06	0.000103	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYCS—liver cancer	9.85e-06	0.000102	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTA1—liver cancer	9.82e-06	0.000102	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP1A1—liver cancer	9.78e-06	0.000101	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—liver cancer	9.73e-06	0.000101	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NAT2—liver cancer	9.71e-06	0.000101	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	9.68e-06	0.0001	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP2E1—liver cancer	9.68e-06	0.0001	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTP1—liver cancer	9.67e-06	0.0001	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GGT1—liver cancer	9.66e-06	0.0001	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GOT1—liver cancer	9.66e-06	0.0001	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYCS—liver cancer	9.61e-06	9.96e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KDR—liver cancer	9.6e-06	9.96e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP2E1—liver cancer	9.59e-06	9.95e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK14—liver cancer	9.54e-06	9.89e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—HMOX1—liver cancer	9.53e-06	9.89e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GGT1—liver cancer	9.43e-06	9.78e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GOT1—liver cancer	9.43e-06	9.78e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ESR1—liver cancer	9.36e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—MTHFR—liver cancer	9.33e-06	9.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALDOB—liver cancer	9.31e-06	9.65e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	9.29e-06	9.63e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—F2—liver cancer	9.24e-06	9.58e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2—liver cancer	9.15e-06	9.49e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARA—liver cancer	9.15e-06	9.49e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TERT—liver cancer	9.12e-06	9.45e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—MTHFR—liver cancer	9.12e-06	9.45e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	9.11e-06	9.44e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYCS—liver cancer	9.06e-06	9.39e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.99e-06	9.32e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYCS—liver cancer	8.98e-06	9.31e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PSMD10—liver cancer	8.96e-06	9.3e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PSMA4—liver cancer	8.96e-06	9.3e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARA—liver cancer	8.94e-06	9.27e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TGFB1—liver cancer	8.93e-06	9.26e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GOT1—liver cancer	8.89e-06	9.21e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GGT1—liver cancer	8.89e-06	9.21e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTM1—liver cancer	8.88e-06	9.21e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CRABP1—liver cancer	8.88e-06	9.21e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APC—liver cancer	8.85e-06	9.17e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CG—liver cancer	8.85e-06	9.17e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GOT1—liver cancer	8.81e-06	9.13e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GGT1—liver cancer	8.81e-06	9.13e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GOT2—liver cancer	8.72e-06	9.04e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTP1—liver cancer	8.68e-06	9e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—HMOX1—liver cancer	8.56e-06	8.87e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTP1—liver cancer	8.47e-06	8.78e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP1A1—liver cancer	8.42e-06	8.73e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—HMOX1—liver cancer	8.35e-06	8.66e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KDR—liver cancer	8.34e-06	8.65e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—BRAF—liver cancer	8.32e-06	8.62e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK14—liver cancer	8.28e-06	8.59e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—KRAS—liver cancer	8.27e-06	8.58e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP2E1—liver cancer	8.2e-06	8.5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ESR1—liver cancer	8.13e-06	8.43e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—F2—liver cancer	8.03e-06	8.32e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—liver cancer	7.98e-06	8.28e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTM1—liver cancer	7.97e-06	8.27e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.94e-06	8.23e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—liver cancer	7.91e-06	8.2e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—HMOX1—liver cancer	7.87e-06	8.16e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—MTHFR—liver cancer	7.85e-06	8.14e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—liver cancer	7.84e-06	8.13e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—HMOX1—liver cancer	7.8e-06	8.09e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTM1—liver cancer	7.78e-06	8.07e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CD—liver cancer	7.78e-06	8.06e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HPGDS—liver cancer	7.76e-06	8.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—liver cancer	7.7e-06	7.99e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARA—liver cancer	7.7e-06	7.99e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SERPINE1—liver cancer	7.69e-06	7.98e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APC—liver cancer	7.68e-06	7.97e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—liver cancer	7.68e-06	7.97e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYCS—liver cancer	7.67e-06	7.95e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—liver cancer	7.66e-06	7.94e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—liver cancer	7.61e-06	7.89e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—liver cancer	7.6e-06	7.88e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARG—liver cancer	7.56e-06	7.84e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1A1—liver cancer	7.56e-06	7.84e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GGT1—liver cancer	7.53e-06	7.81e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GOT1—liver cancer	7.53e-06	7.81e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARG—liver cancer	7.39e-06	7.66e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1A1—liver cancer	7.38e-06	7.65e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—liver cancer	7.35e-06	7.62e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—liver cancer	7.33e-06	7.61e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—liver cancer	7.27e-06	7.54e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BRAF—liver cancer	7.22e-06	7.49e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—MTHFR—liver cancer	7.05e-06	7.31e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—liver cancer	7.03e-06	7.29e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—liver cancer	7e-06	7.25e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1A1—liver cancer	6.95e-06	7.21e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RAF1—liver cancer	6.94e-06	7.2e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.92e-06	7.17e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PSMA4—liver cancer	6.92e-06	7.17e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PSMD10—liver cancer	6.92e-06	7.17e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARA—liver cancer	6.91e-06	7.17e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1A1—liver cancer	6.89e-06	7.15e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CD—liver cancer	6.89e-06	7.14e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—MTHFR—liver cancer	6.88e-06	7.13e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—liver cancer	6.8e-06	7.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MTOR—liver cancer	6.78e-06	7.03e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CB—liver cancer	6.78e-06	7.03e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—liver cancer	6.76e-06	7.01e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CD—liver cancer	6.75e-06	7e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARA—liver cancer	6.75e-06	7e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CD—liver cancer	6.73e-06	6.98e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GOT2—liver cancer	6.73e-06	6.98e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	6.69e-06	6.94e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SERPINE1—liver cancer	6.68e-06	6.93e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HMOX1—liver cancer	6.67e-06	6.91e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—liver cancer	6.65e-06	6.89e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—liver cancer	6.61e-06	6.86e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—liver cancer	6.6e-06	6.84e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—MTHFR—liver cancer	6.48e-06	6.72e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—liver cancer	6.47e-06	6.71e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—MTHFR—liver cancer	6.43e-06	6.66e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARG—liver cancer	6.37e-06	6.6e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1B—liver cancer	6.36e-06	6.6e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARA—liver cancer	6.36e-06	6.59e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2E1—liver cancer	6.33e-06	6.56e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARA—liver cancer	6.3e-06	6.54e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—liver cancer	6.29e-06	6.52e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—liver cancer	6.23e-06	6.46e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—liver cancer	6.23e-06	6.45e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—liver cancer	6.21e-06	6.44e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.21e-06	6.44e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—liver cancer	6.21e-06	6.44e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—liver cancer	6.19e-06	6.42e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	6.07e-06	6.3e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—liver cancer	6.07e-06	6.29e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JUN—liver cancer	6.06e-06	6.28e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RAF1—liver cancer	6.03e-06	6.25e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CTNNB1—liver cancer	6.01e-06	6.23e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CB—liver cancer	6e-06	6.23e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—liver cancer	5.92e-06	6.14e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYCS—liver cancer	5.92e-06	6.14e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—liver cancer	5.89e-06	6.11e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1A1—liver cancer	5.89e-06	6.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CB—liver cancer	5.89e-06	6.1e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MTOR—liver cancer	5.89e-06	6.1e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1A—liver cancer	5.87e-06	6.09e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CB—liver cancer	5.87e-06	6.09e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GOT1—liver cancer	5.81e-06	6.02e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GGT1—liver cancer	5.81e-06	6.02e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CD—liver cancer	5.8e-06	6.01e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—liver cancer	5.78e-06	5.99e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK8—liver cancer	5.73e-06	5.94e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARG—liver cancer	5.72e-06	5.93e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—liver cancer	5.71e-06	5.93e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.66e-06	5.87e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—liver cancer	5.62e-06	5.83e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARG—liver cancer	5.58e-06	5.78e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1B—liver cancer	5.52e-06	5.73e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—MTHFR—liver cancer	5.49e-06	5.69e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—liver cancer	5.46e-06	5.67e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—liver cancer	5.45e-06	5.65e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—liver cancer	5.41e-06	5.61e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—liver cancer	5.41e-06	5.61e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—liver cancer	5.4e-06	5.6e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARA—liver cancer	5.39e-06	5.59e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—liver cancer	5.38e-06	5.58e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—liver cancer	5.29e-06	5.49e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—liver cancer	5.27e-06	5.46e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUN—liver cancer	5.26e-06	5.45e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARG—liver cancer	5.26e-06	5.45e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—liver cancer	5.24e-06	5.43e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CTNNB1—liver cancer	5.22e-06	5.41e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—liver cancer	5.22e-06	5.41e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARG—liver cancer	5.21e-06	5.4e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CD—liver cancer	5.21e-06	5.4e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HMOX1—liver cancer	5.15e-06	5.34e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—liver cancer	5.14e-06	5.33e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—liver cancer	5.12e-06	5.3e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1A—liver cancer	5.1e-06	5.29e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CD—liver cancer	5.08e-06	5.27e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CB—liver cancer	5.05e-06	5.24e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—liver cancer	5.02e-06	5.2e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK8—liver cancer	4.98e-06	5.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—liver cancer	4.96e-06	5.15e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—liver cancer	4.87e-06	5.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFB1—liver cancer	4.86e-06	5.03e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.84e-06	5.02e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—liver cancer	4.8e-06	4.97e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CD—liver cancer	4.79e-06	4.96e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CD—liver cancer	4.75e-06	4.92e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—liver cancer	4.73e-06	4.9e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—liver cancer	4.69e-06	4.86e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—liver cancer	4.61e-06	4.78e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—liver cancer	4.59e-06	4.76e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—liver cancer	4.55e-06	4.72e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1A1—liver cancer	4.55e-06	4.71e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CB—liver cancer	4.54e-06	4.7e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—liver cancer	4.5e-06	4.66e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARG—liver cancer	4.45e-06	4.62e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CB—liver cancer	4.43e-06	4.59e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MTHFR—liver cancer	4.24e-06	4.39e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—liver cancer	4.23e-06	4.38e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFB1—liver cancer	4.22e-06	4.37e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CB—liver cancer	4.17e-06	4.33e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARA—liver cancer	4.16e-06	4.31e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CB—liver cancer	4.14e-06	4.29e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—liver cancer	4.13e-06	4.28e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CD—liver cancer	4.06e-06	4.21e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—liver cancer	4e-06	4.15e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—liver cancer	4e-06	4.14e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—liver cancer	3.91e-06	4.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—liver cancer	3.82e-06	3.96e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—liver cancer	3.66e-06	3.8e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—liver cancer	3.66e-06	3.79e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—liver cancer	3.59e-06	3.72e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—liver cancer	3.58e-06	3.71e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—liver cancer	3.56e-06	3.69e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CB—liver cancer	3.54e-06	3.67e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—liver cancer	3.47e-06	3.6e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARG—liver cancer	3.44e-06	3.56e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—liver cancer	3.38e-06	3.5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—liver cancer	3.32e-06	3.44e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—liver cancer	3.18e-06	3.29e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CD—liver cancer	3.13e-06	3.25e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—liver cancer	3.09e-06	3.2e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—liver cancer	3.08e-06	3.19e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—liver cancer	2.99e-06	3.1e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—liver cancer	2.93e-06	3.04e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—liver cancer	2.92e-06	3.03e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—liver cancer	2.77e-06	2.87e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CB—liver cancer	2.73e-06	2.83e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—liver cancer	2.7e-06	2.8e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—liver cancer	2.54e-06	2.64e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—liver cancer	2.52e-06	2.62e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—liver cancer	2.52e-06	2.61e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—liver cancer	2.26e-06	2.34e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—liver cancer	2.21e-06	2.29e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—liver cancer	2.16e-06	2.23e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—liver cancer	2.08e-06	2.15e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—liver cancer	2.06e-06	2.14e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—liver cancer	1.76e-06	1.83e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—liver cancer	1.66e-06	1.72e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—liver cancer	1.36e-06	1.41e-05	CbGpPWpGaD
